NYSE:WATLife Sciences
What Waters (WAT)'s Diagnostics Wins and Q1 Beat Mean For Shareholders
Waters Corporation recently reported a strong first quarter of 2026, with adjusted earnings per share up 20% and revenues rising very large, lifted by the early contribution of the acquired BD Biosciences and Diagnostic Solutions businesses.
At the same time, Waters advanced its technology and diagnostics portfolio with FDA 510(k) clearance for the BD BACTEC FXI Culture System and the launch of two high-performance mass spectrometry platforms aimed at complex multiomics and imaging...